STOCK TITAN

ANGLE plc - $ANPCY STOCK NEWS

Welcome to our dedicated page for ANGLE plc news (Ticker: $ANPCY), a resource for investors and traders seeking the latest updates and insights on ANGLE plc stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ANGLE plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ANGLE plc's position in the market.

Rhea-AI Summary
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) launches Portrait+ CTC staining kit, combining Parsortix technology with an immunofluorescent assay for precise CTC identification, characterisation, and enumeration. The test is designed for accurate, repeatable results and can be used in breast, lung, prostate, and ovarian cancers. EMT transition step in cancer cells is also detected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.87%
Tags
none
-
Rhea-AI Summary
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) expects a 120% increase in revenue for 2023 to c. £2.2 million, with sales secured in 2023 expected to be c. £3.3 million. Revenue for 2024 is expected to triple compared to 2023. The cash runway has been extended into Q2 2025. The streamlining of the Services business is expected to result in cost savings of c. £3 million per annum in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) announces the launch of its Portrait PD-L1 test, a minimally invasive liquid biopsy using CTCs from the Parsortix system to determine PD-L1 status in cancer patients. The test aims to provide accurate, repeatable, and precise results for CTC PD-L1 biomarker expression, allowing real-time assessment of the biomarker status, which may address the fundamental flaw in current PD-L1 tests via a simple blood test. The global PD-1 and PD-L1 immunotherapy market is currently valued at US $36.9 billion per annum, and analysts predict the market to reach US $109.1 billion by 2032.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
ANGLE plc announces the publication of a study using the Parsortix system that sheds new light on the characteristics of circulating tumor cells (CTCs) in Head and Neck Squamous Cell Carcinoma (HNSCC). The study demonstrates the feasibility of using mass cytometry for the comprehensive characterization of CTCs captured by the Parsortix system, providing a deep understanding of their phenotypic status and diversity. The findings offer the potential for the development of more precise and personalized treatment strategies for HNSCC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
PARSORTIX SYSTEM OUTPERFORMS CURRENT LABORATORY STANDARD FOR DISSEMINATED TUMOUR CELL HARVEST
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
none
-
Rhea-AI Summary
ANGLE plc showcased the Parsortix system at the Advances in Circulating Tumor Cells conference, receiving positive feedback. Key highlights include predictive CTC biomarkers for treatment resistance in NSCLC, clinical significance of mesenchymal CTCs, and dual analysis of CTCs and ctDNA. ANGLE plans to expand translational research use and grow biopharma services business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
ANGLE plc announces interim results for the period ended 30 June 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
none
-
Rhea-AI Summary
ANGLE plc announces launch of Portrait Flex assay
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.56%
Tags
none
ANGLE plc

OTC:ANPCY

ANPCY Rankings

ANPCY Stock Data

49.25M
201.15M
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
Guildford